Titus Health Care, based in the Netherlands, is a leader in women's health care. With a strong commitment to innovation and a large clinical network, they are the ideal partner to facilitate women's access to Carevix^® increase.

Joep de Mönnink, founder and managing director of Titus Health Care, says: "At Titus Health Care, we are committed to improving women's lives every day. We introduce new gynaecological products and train healthcare providers. In doing so, we provide innovative solutions that improve the experience of women and their healthcare providers. Carevix^® is an important step towards a more respectful, pain-aware gynaecology. We are proud to announce Carevix^® to be introduced in the Benelux, giving women a choice when it comes to reducing anxiety, pain and bleeding during IUD placement."

Mathieu Horras, CEO and co-founder of ASPIVIX, added: "We are proud of our partnership with Titus Health Care, whose reputation and reach in the Benelux region will facilitate access to Carevix^® will accelerate. Together, we are enabling a shift to milder, more modern care, allowing women to make informed choices by placing an IUD without fear of pain and bleeding."

With this agreement, ASPIVIX strengthens its growing position in Europe. The launch of Carevix^® in the Netherlands and Belgium represents a major step forward in redefining gynaecological procedures that put patient comfort at the centre: from IUD placements to IVF treatments.

Aspivix is a leading leader in women's health and is committed to modernising healthcare solutions for women worldwide. Focused on innovation, Aspivix develops advanced medical devices, such as Carevix^®, transforming the gynaecological experience by providing safer and less painful solutions that improve the quality of care and empower women to take charge of their health.

More information at: www.aspivix.com.

Carevix^® is an innovative soft suction cervical device designed as a modern and softer alternative to the traditional cervical tenaculum that significantly reduces trauma, pain and bleeding associated with transcervical procedures. Carevix^® has received FDA approval, CE marking, MHRA and ANVISA approval and is now available in Switzerland, UK, Benelux; other countries will follow in the coming months.

Carevix^® is clinically proven non-traumatic during transcervical procedures, with convincing results from ADVANCE Women, a multi-site randomised controlled trial of Carevix^®, used in IUD procedures against the cervical tenaculum¹. The study was published in "Contraception", the International Reproductive Health Journal in 2023.

Carevix^® was recognised by TIME Magazine as one of the best inventions of 2024 and was awarded, among others, the iF Design Award 2022, one of the most important and prestigious design awards in the world.

Reference:
1. Michal Yaron, Hélène Legardeur, Bastien Barcellini, Farida Akhoundova, Patrice Mathevet, Safety and efficacy of a suction cervical stabiliser for IUD insertion: results from a randomised, controlled study, Contraception, 2023, 110004, ISSN 0010- 7824, Contraception link.

Titus Health Care introduces new gynaecological products and provides training to improve women's healthcare. In 2010, Titus Health Care introduced the T-Safe copper IUD in the Netherlands for women seeking hormone-free contraception. Over the years, its product range has expanded significantly. Since 2021, Titus Health Care has also been a distributor in Belgium. Every year, Titus Health Care educates and trains thousands of healthcare professionals on the placement of long-acting contraceptives and advises them on contraception.

More information at www.titushealthcare.nl.